Sinopharm Group Co Ltd is a leading Chinese pharmaceutical and healthcare company with a significant presence in the global market. ## Company Overview - Founded: 2003 - Headquarters: Shanghai, China - Parent Company: China National Pharmaceutical Group Corporation (CNPGC) - Listed on: Hong Kong Stock Exchange (stock code: 1099.HK) - Global Ranking: 109th in the 2021 Fortune Global 500 list ## Business Segments Sinopharm operates through four main segments: 1. Pharmaceutical Distribution 2. Medical Device Distribution 3. Retail Pharmacy 4. Other Business (manufacturing and sale of pharmaceuticals, chemical reagents, and laboratory supplies) ## Key Operations ### Distribution Network - Largest medicine distribution network in China - Covers 23 provinces, municipalities, and autonomous regions - Serves approximately 42.23% of all hospitals in China, including 64.18% of class-three hospitals ### Retail Pharmacy - Operates a network of retail drug stores through direct operations and franchises - Present in major cities throughout China ### COVID-19 Vaccine - Developed the Sinopharm BIBP COVID-19 vaccine (BBIBP-CorV) - Received WHO emergency use approval on May 7, 2021 ## Financial Performance Q3 2024 Highlights: - Revenue: CNY 294,726.81 million (6.3% decrease year-over-year) - Net Income: CNY 3,703.88 million (9.8% decrease year-over-year) - Basic EPS: CNY 1.19 (9.8% decrease year-over-year) ## Strategic Initiatives - Expanding distribution network through mergers and acquisitions - Focusing on pharmaceutical supply chain management - Investing in research and development of new pharmaceutical products - Expanding retail pharmacy operations across China Sinopharm Group continues to strengthen its position as a leading pharmaceutical distributor and healthcare service provider in China, leveraging its extensive network and diverse business segments to capitalize on the growing healthcare market.